Latest Biomarkers News

UBM Canon and MD+DI Proudly Announce 25 Innovative Products as Winners of the 2012 Medical Design Excellence AwardsPHILADELPHIA, May 25, 2012 /PRNewswire/ -- The winning products in this year's Medical Design Excellence Awards (MDEA) competition, presented by UBM Canon, were announced at a presentation ceremony held May 23 inside the Philadelphia Marriott Downtown hotel. The ceremony was held in conjunction with the MD&M East Event (www.MDMEast.com) at the adjacent Pennsylvania Convention Center. At the ce...

Japan’s Panasonic, University Develop New Way To Detect Lung CancerPanasonic and Japan’s Nagoya University say they have developed a method for identifying lung cancer, a test with an accuracy rate of 95%, by relying on urine-based biomarkers.

Partnership aims to develop diagnostic for lupus flaresXDx is collaborating with LabCorp to create and market a biomarker-based assay for lupus flares. -More-

Researchers Detect Predictive Biomarkers Of The Fertilizing Capacity Of Sperm DonorsThe study represents a breakthrough in understanding the causes of unexplained infertility The diagnosis of male fertility is usually performed through the observation of the sperm in the microscope. However, normal quality semen does not guarantee a...

NORD Calls Senate Bill Most Important Since Orphan Drug ActPraises Senate for Addressing Needs of Rare Disease Patients WASHINGTON, May 24, 2012 /PRNewswire-USNewswire/ -- The National Organization for Rare Disorders (NORD) applauds legislation passed today by the U.S. Senate -- S 3187, the Food and Drug Administration Safety & Innovation Act of 2012 (FDASIA) – and says it contains the most comprehensive improvements to public policy f...

Markers Pinpoint Crohn's Relapse After Infliximab (CME/CE)SAN DIEGO (MedPage Today) -- The sudden elevation of two biomarkers predicted Crohn's disease relapse in patients who achieved remission after treatment with the tumor necrosis factor inhibitor.

Exciting New Research Results Reported at the Recent European Society of Cardiology Heart Failure Congress in BelgradeCritical Diagnostics, makers of the Presage® ST2 Assay, announced today that ST2, an emerging heart disease biomarker, remains at the forefront in cardiology clinical research. At the recently concluded European Heart Failure Congress results describing the clinical utility of ST2 in patients with heart failure were reported in six different summaries....

Who pays for personalized medicine?While researchers are busy identifying new biomarkers to detect disease and tailor treatments to individual needs, legal battles have been waged all the way up to the Supreme Court, trying to sort out whether a private company can own the rights to a...

Firefly Bags $500K from Massachusetts Life Science Center for miRNA Biomarker Platform

Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter Preclinical Development in Acute Leukemia and Other Hematological CancersOryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of hematological cancers. LSD1 inhibition reduced tumor load especially in acute leukemia models by targeting Leukemia Stem Cells, while normal myeloid progenitor cells were spared. Barcelona, Spain (PRWEB) May...

Amgen Revives Drug Thanks to Biomarker DataBloomberg | In light of a small set of data, Amgen is reviving its gastric cancer drug rilotumumab that seems to show efficacy for patients with high levels of c-Met, a protein linked to cancer growth. The revival is a win for personalized medicine....

Firefly BioWorks receives MLSC grant to commercialize new microRNA detection technologyFirefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center.

Firefly BioWorks, Inc. Announces the Award of a $500K Grant from the Massachusetts Life Sciences CenterFirefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center. The award was granted through the Center's Small Business Matching Grant Program, which was created to accelerate the commercialization of new products for companies th...

True Diagnostics Receives CE Mark for TrueDX(TM) Platform & TSH Test SAN DIEGO, CA -- (Marketwire) -- 05/24/12 -- True Diagnostics, Inc. (www.TrueDiagnostics.com) has announced it has received a CE Mark to allow it to distribute its TrueDX Platform and quantitative TSH (Thyroid Stimulating Hormone) test in Europe. With the TrueDX Platform, doctors can immediately determine if a patient suffers from a hypoactive thyroid by using only a finger prick of blood. Thi...

EnteromeEnterome will use its metagenomics platform to develop drugs that target the effects of alterations in the microbiota, and to identify, develop and commercialize biomarkers. The company's biomarkers will be used to develop diagnostics, and to stratif...

Potential To Diagnose Radiation Exposure Using Novel BiomarkersResearchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and tr...

LabCorp, XDx in deal for lupus flare predictive testLaboratory Corp. of America Holdings (NYSE:LH) and XDx Inc. (Brisbane, Calif.) partnered to discover biomarkers to predict flares of systemic lupus erythematosus (SLE) and develop a predictive test based on the markers. The partners said the deal com...

Halo Healthcare, Inc., Makers of the HALO® Breast Test for Risk Assessment and Early Detection of Breast Cancer, Announces New OrganizationHalo Healthcare, Inc. (the “Company”) announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO® diagnostic device for breast cancer risk assessment. The Company manufactures the FDA-cleared HALO® Breast Test...

ECOG Foundation Awards Young Investigators for Research InitiativesYoung researchers affiliated with Indiana University and the University of Pennsylvania. Philadelphia, PA (PRWEB) May 23, 2012 The Eastern Cooperative Oncology Group (ECOG) Research and Education Foundation has announced the recipients of its annual research awards for young investigators. These awards relate to the mission of the foundation to fund scientific research into the causes and treatme...

GDS International Paves the Way for the Pharmaceutical Industry at its Upcoming NGP Summit in TexasAUSTIN, Texas, May 23, 2012 /PRNewswire/ -- On 23rd to 25th of July, a selection of the region's most prominent C-level executives from across the pharmaceutical industry will convene at the Barton Creek Resort and Spa, Austin, Texas, to attend GDS International's tenth Next Generation Pharmaceuticals summit (NGP). This year, NGP has elected 30 of the most well-respected decision makers fr...

XDx and LabCorp Enter Into Collaboration and License Agreement to Develop Lupus Flare Predictor TestXDx, Inc. announced today that it has entered into a collaboration and license agreement with Laboratory Corporation of America® Holdings (LabCorp) (NYSE: LH) whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). The agreement combines...

Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate CancerNEW YORK, May 23, 2012 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients' urine to detect and manage prostate cancer. In the first study, the presence of a prostate canc...

AVEO Initiates Phase 1 Study of AV-203, an ERBB3 Inhibitory Antibody, in Advanced Solid TumorsAVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors. AV-203 is a monoclonal antibody that selectively targets the receptor ERBB3, a new and promising strategy for treating cancer. AV-203 was developed through...

AVEO commences AV-203 Phase 1 study in advanced solid tumorsAVEO Oncology today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

Scientists identify key mechanism in development of Alzheimer'sNew research by scientists at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM) demonstrates how dying or damaged brain cells release debris into the bloodstream and give rise to specific autoantibodies...

0 1 2 3 4 ›»

buy Biomarkers market research data and corporate reports now Advertisement